Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Uesugi, N.
Right arrow Articles by Takebayashi, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Uesugi, N.
Right arrow Articles by Takebayashi, S.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2000) 15: 355-365
© 2000 European Renal Association-European Dialysis and Transplant Association

Glycoxidative modification of AA amyloid deposits in renal tissue

Noriko Uesugi1, Noriyuki Sakata1, Ryoji Nagai2, Tadashi Jono2, Seikoh Horiuchi2 and Shigeo Takebayashi1

1 Second Department of Pathology, School of Medicine, Fukuoka University, 7–45–1 Nanakuma, Jonan-ku, Fukuoka 814–0133, Japan and 2 Department of Biochemistry, Kumamoto University School of Medicine, Honjo, 2–2-1, Kumamoto, 860–0166, Japan

Correspondence and offprint requests to: Professor S. Takebayashi, MD, Second Department of Pathology, School of Medicine, Fukuoka University, 7–45–1 Nanakuma, Jonan-ku, Fukuoka, 814–0133, Japan.

Background. N{varepsilon}-carboxymethyllysine (CML) is a product of the oxidative modification of glycated proteins, which damages proteins with ageing, diabetes, uraemia and Alzheimer's disease. In contrast, pyrraline is one of the advanced glycation end products, which is independent of oxidative processes. CML has been identified in ß-amyloid of Alzheimer's disease and ß2-microglobulin-associated amyloid. We investigated whether CML and pyrraline are formed in AA and AL amyloid of the kidney.

Method. Renal specimens from 19 cases of AA amyloidosis and 14 cases of AL amyloidosis were investigated for immunolocalization of CML, pyrraline, collagen type IV and laminin in amyloid deposits. Renal biopsies of 10 age-matched cases with thin basement membrane disease and normal renal function were used as controls. The fractional areas of amyloid, CML, laminin and collagen IV in glomeruli and interstitium (%amyloid, %CML, %laminin and %collagen, respectively) were calculated using the point counting method. The correlation between these parameters was evaluated using Spearman's rank correlation test.

Results. CML colocalized with AA amyloid, but not AL amyloid, except in two cases of the latter with a long history of nephropathy exceeding 14 years. In contrast, pyrraline was not observed in either type of amyloid. Mean %CML in AA amyloid was significantly higher than %collagen and %laminin in glomeruli and interstitium, indicating that AA amyloid is modified by CML independent of colocalized extracellular matrix. %CML significantly correlated with %amyloid both in glomeruli and interstitium in AA amyloidosis. AL amyloid cases with a long history of nephropathy showed positive staining for CML in glomeruli and interstitium but no staining for collagen IV and laminin in amyloid deposits.

Conclusion. CML modification may occur in amyloid deposits of AA amyloidosis, independent of extracellular matrix components. Glycoxidative modification may have a functional link to AA amyloid deposition in renal tissues.

Keywords: AA amyloid; CML; extracellular matrix; glycoxidative modification; kidney


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Am. J. Pathol.Home page
C. Rocken, R. Kientsch-Engel, S. Mansfeld, B. Stix, K. Stubenrauch, B. Weigle, F. Buhling, M. Schwan, and W. Saeger
Advanced Glycation End Products and Receptor for Advanced Glycation End Products in AA Amyloidosis
Am. J. Pathol., April 1, 2003; 162(4): 1213 - 1220.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
N. Sakata, N. Uesugi, S. Takebayashi, R. Nagai, T. Jono, S. Horiuchi, M. Takeya, H. Itabe, T. Takano, T. Myint, et al.
Glycoxidation and lipid peroxidation of low-density lipoprotein can synergistically enhance atherogenesis
Cardiovasc Res, February 1, 2001; 49(2): 466 - 475.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.